EPRX (Eupraxia Pharmaceuticals) Other Long-Term Liabilities: $-0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EPRX Eupraxia Pharmaceuticals Inc EPRX
34 GF Score
Price $7.42
! 1 Warning Sign
View Full Analysis

What is Eupraxia Pharmaceuticals Other Long-Term Liabilities?

Eupraxia Pharmaceuticals EPRX -0.27% 34 Other Long-Term Liabilities is $-0.00 Mil as of Jun. 2026. GuruFocus rates EPRX with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

Eupraxia Pharmaceuticals's other long-term liabilities for the quarter that ended in Jun. 2026 was $-0.00 Mil.

Eupraxia Pharmaceuticals's quarterly other long-term liabilities increased from Dec. 2025 ($-0.00 Mil) to Mar. 2026 ($0.00 Mil) but then declined from Mar. 2026 ($0.00 Mil) to Jun. 2026 ($-0.00 Mil).

Eupraxia Pharmaceuticals's annual other long-term liabilities stayed the same from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then declined from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($-0.00 Mil).

Eupraxia Pharmaceuticals Other Long-Term Liabilities Related Terms

Eupraxia Pharmaceuticals Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Eupraxia Pharmaceuticals's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eupraxia Pharmaceuticals Other Long-Term Liabilities Chart

Eupraxia Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only -0.00 0.00 0.00 0.00 -0.00

Eupraxia Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 -0.00 0.00 -0.00
EPRX
34GF Score
Eupraxia Pharmaceuticals Inc EPRX
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eupraxia Pharmaceuticals Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $-0.00 Mil mean?
Eupraxia Pharmaceuticals (EPRX) has a Other Long-Term Liabilities of $-0.00 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Eupraxia Pharmaceuticals and its competitors.
Is Eupraxia Pharmaceuticals' Other Long-Term Liabilities too high?
Eupraxia Pharmaceuticals' current Other Long-Term Liabilities is $-0.00 Mil. Overall, Eupraxia Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Eupraxia Pharmaceuticals' Other Long-Term Liabilities compare to VRTX and REGN?
Eupraxia Pharmaceuticals' Other Long-Term Liabilities of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Eupraxia Pharmaceuticals and its competitors. Eupraxia Pharmaceuticals's current Other Long-Term Liabilities is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eupraxia Pharmaceuticals stock overvalued right now?
Eupraxia Pharmaceuticals (EPRX) has a current Other Long-Term Liabilities of $-0.00 Mil. The current Other Long-Term Liabilities is $-0.00 Mil. Eupraxia Pharmaceuticals' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Eupraxia Pharmaceuticals (EPRX), the current Other Long-Term Liabilities is $-0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eupraxia Pharmaceuticals Business Description

Other Exchanges X43:GermanyEPRX:Canada
Address 201 2067 Cadboro Bay Road, Victoria, BC, CAN, V8R 5G4
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
34GF Score

Get the complete analysis for EPRX

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.42
Price